Revolution Medicines Inc Ordinary Shares RVMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RVMD is a good fit for your portfolio.
News
-
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
-
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
-
Revolution Medicines to Participate in Upcoming Investor Conferences
-
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
-
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
-
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
-
Revolution Medicines to Participate in Upcoming Investor Conferences
-
Revolution Medicines to acquire EQRx in deal that will add $1 billion in cash to its balance sheet to fund R&D
Trading Information
- Previous Close Price
- $35.33
- Day Range
- $34.65–36.36
- 52-Week Range
- $15.44–38.73
- Bid/Ask
- $36.05 / $39.00
- Market Cap
- $5.92 Bil
- Volume/Avg
- 1.2 Mil / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 347.76
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 378
- Website
- https://www.revmed.com
Comparables
Valuation
|
Metric
|
RVMD
|
ITOS
|
VOR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.21 | 0.67 | 0.76 |
Price/Sales | 347.76 | 30.67 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
RVMD
ITOS
VOR
Financial Strength
|
Metric
|
RVMD
|
ITOS
|
VOR
|
|---|---|---|---|
Quick Ratio | 12.89 | 13.46 | 8.81 |
Current Ratio | 13.06 | 13.76 | 9.04 |
Interest Coverage | −1,607.49 | — | — |
Quick Ratio
RVMD
ITOS
VOR
Profitability
|
Metric
|
RVMD
|
ITOS
|
VOR
|
|---|---|---|---|
Return on Assets (Normalized) | −31.22% | −12.92% | −41.83% |
Return on Equity (Normalized) | −35.83% | −14.67% | −51.69% |
Return on Invested Capital (Normalized) | −37.83% | −18.54% | −47.03% |
Return on Assets
RVMD
ITOS
VOR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ylgvtzvw | Pgfbw | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pnnvpmry | Yxbxt | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vghwtwnqv | Lllmlwq | $97.8 Bil | |
MRNA
| Moderna Inc | Fmhsygt | Ctrc | $41.3 Bil | |
ARGX
| argenx SE ADR | Nqkbtrg | Gvjj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nxdbzsbt | Kgwt | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pfscpyb | Pjlkvhh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Brmrhlhf | Xhfzj | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rhgjfwbtlm | Yjybnw | $12.5 Bil | |
INCY
| Incyte Corp | Pqtvylyh | Ttwsks | $11.6 Bil |